NGMUnknown
NGM BIOPHARMACEUTICALS INC Insider Trading Activity
Every SEC Form 4 insider transaction reported for NGM BIOPHARMACEUTICALS INC (NGM), sourced directly from SEC EDGAR and updated as new filings are accepted.
By Trabud · Insider-trading data from SEC EDGAR
Latest filing:
Compiled automatically from SEC EDGAR Form 4 filings and refreshed daily. Figures count purchases (code P) and sales (code S) only — not grants, option exercises, or gifts. How this page is built. Not investment advice.
Quick Answer
Are NGM insiders buying or selling?
NGM BIOPHARMACEUTICALS INC insiders reported no open-market purchases or sales in the last 12 months. Since April 2019, Trabud has recorded 227 Form 4 filings for NGM: 203 buys ($363.7M) and 24 sells ($12.8M).
Source: SEC EDGAR Form 4
Key Statistics (April 2019 – Nov 17, 2023)
Total Form 4 filings
227
SEC EDGAR
Insider filers
8
Insider buys (203)
$363.7M
Insider sells (24)
$12.8M
Insider sentiment
Net buyingNet insider flow of $350.9M in net buying since April 2019.
Recent NGM insider transactions
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Nov 17, 2023 | COLUMN GROUP L P | Director, 10% Owner | Purchase | 22.6K | $0.69 | $15.5K | SEC ↗ |
| Nov 17, 2023 | COLUMN GROUP L P | Director, 10% Owner | Purchase | 22.6K | $0.69 | $15.5K | SEC ↗ |
| Nov 17, 2023 | Peter Svennilson | Director, 10% Owner | Purchase | 22.6K | $0.69 | $15.5K | SEC ↗ |
| Nov 17, 2023 | David V Goeddel | Director, 10% Owner | Purchase | 26.8K | $0.68 | $18.3K | SEC ↗ |
| Feb 1, 2023 | COLUMN GROUP L P | Director, 10% Owner | Purchase | 184.3K | $5.00 | $921.1K | SEC ↗ |
| Feb 1, 2023 | COLUMN GROUP L P | Director, 10% Owner | Purchase | 184.3K | $5.00 | $921.1K | SEC ↗ |
| Feb 1, 2023 | Peter Svennilson | Director, 10% Owner | Purchase | 184.3K | $5.00 | $921.1K | SEC ↗ |
| Feb 1, 2023 | David V Goeddel | Director, 10% Owner | Purchase | 184.3K | $5.00 | $921.1K | SEC ↗ |
| Jan 23, 2023 | COLUMN GROUP L P | Director, 10% Owner | Purchase | 38.1K | $5.00 | $190.6K | SEC ↗ |
| Jan 23, 2023 | COLUMN GROUP L P | Director, 10% Owner | Purchase | 38.1K | $5.00 | $190.6K | SEC ↗ |
| Jan 23, 2023 | Peter Svennilson | Director, 10% Owner | Purchase | 38.1K | $5.00 | $190.6K | SEC ↗ |
| Jan 23, 2023 | David V Goeddel | Director, 10% Owner | Purchase | 38.1K | $5.00 | $190.6K | SEC ↗ |
| Jan 18, 2023 | Jin-Long Chen | Chief Scientific Officer | Sale | 85.1K | $5.15 | $438.3K | SEC ↗ |
| Jan 17, 2023 | COLUMN GROUP L P | Director, 10% Owner | Purchase | 5.4K | $4.95 | $26.6K | SEC ↗ |
| Jan 17, 2023 | COLUMN GROUP L P | Director, 10% Owner | Purchase | 5.4K | $4.95 | $26.6K | SEC ↗ |
| Jan 17, 2023 | Peter Svennilson | Director, 10% Owner | Purchase | 5.4K | $4.95 | $26.6K | SEC ↗ |
| Jan 17, 2023 | David V Goeddel | Director, 10% Owner | Purchase | 5.4K | $4.95 | $26.6K | SEC ↗ |
| Jan 12, 2023 | COLUMN GROUP L P | Director, 10% Owner | Purchase | 309.1K | $4.79 | $1.5M | SEC ↗ |
| Jan 12, 2023 | COLUMN GROUP L P | Director, 10% Owner | Purchase | 309.1K | $4.79 | $1.5M | SEC ↗ |
| Jan 12, 2023 | Peter Svennilson | Director, 10% Owner | Purchase | 309.1K | $4.79 | $1.5M | SEC ↗ |
| Jan 12, 2023 | David V Goeddel | Director, 10% Owner | Purchase | 309.1K | $4.79 | $1.5M | SEC ↗ |
| Dec 14, 2022 | COLUMN GROUP L P | Director, 10% Owner | Purchase | 300 | $4.98 | $1.5K | SEC ↗ |
| Dec 14, 2022 | COLUMN GROUP L P | Director, 10% Owner | Purchase | 300 | $4.98 | $1.5K | SEC ↗ |
| Dec 14, 2022 | Peter Svennilson | Director, 10% Owner | Purchase | 300 | $4.98 | $1.5K | SEC ↗ |
| Dec 14, 2022 | David V Goeddel | Director, 10% Owner | Purchase | 300 | $4.98 | $1.5K | SEC ↗ |
Showing the 25 most recent of 227 Form 4 filings for NGM BIOPHARMACEUTICALS INC.
Most active NGM insiders
- Peter Svennilson115 filings
- David V Goeddel54 filings
- Peter Svennilson32 filings
- Jin-Long Chen20 filings
- Hsiao D Lieu3 filings
Ask anything about NGM insider activity
Use Trabud's AI agent to query NGM BIOPHARMACEUTICALS INC's Form 4 history in plain English — "Show me NGM CEO purchases this year" or compare it against any other ticker.
Open the AI agentNGM insider trading FAQ
Are NGM BIOPHARMACEUTICALS INC insiders buying or selling?
NGM BIOPHARMACEUTICALS INC insiders reported no open-market purchases or sales in the last 12 months. Since April 2019, Trabud has recorded 227 Form 4 filings for NGM: 203 buys ($363.7M) and 24 sells ($12.8M). Over the full record that is net buying of $350.9M.
How many insiders trade NGM stock?
8 distinct insider filers — officers, directors, 10%+ owners, and investment groups filing jointly — have reported Form 4 transactions for NGM BIOPHARMACEUTICALS INC. The most recent filing was accepted on Nov 17, 2023.
Where does Trabud get NGM insider trading data?
All NGM insider trading data comes directly from official SEC EDGAR Form 4 filings, which corporate insiders must submit within two business days of a transaction under Section 16(a) of the Securities Exchange Act of 1934.